356 related articles for article (PubMed ID: 19480873)
1. Driving behaviors among community-dwelling persons with multiple sclerosis.
Schultheis MT; Weisser V; Manning K; Blasco A; Ang J
Arch Phys Med Rehabil; 2009 Jun; 90(6):975-81. PubMed ID: 19480873
[TBL] [Abstract][Full Text] [Related]
2. Examining the relationship between cognition and driving performance in multiple sclerosis.
Schultheis MT; Weisser V; Ang J; Elovic E; Nead R; Sestito N; Fleksher C; Millis SR
Arch Phys Med Rehabil; 2010 Mar; 91(3):465-73. PubMed ID: 20298841
[TBL] [Abstract][Full Text] [Related]
3. Vision and driving in multiple sclerosis.
Schultheis MT; Manning K; Weisser V; Blasco A; Ang J; Wilkinson ME
Arch Phys Med Rehabil; 2010 Feb; 91(2):315-7. PubMed ID: 20159138
[TBL] [Abstract][Full Text] [Related]
4. Actual reality: a new approach to functional assessment in persons with multiple sclerosis.
Goverover Y; O'Brien AR; Moore NB; DeLuca J
Arch Phys Med Rehabil; 2010 Feb; 91(2):252-60. PubMed ID: 20159130
[TBL] [Abstract][Full Text] [Related]
5. The relation between subjective and objective measures of everyday life activities in persons with multiple sclerosis.
Goverover Y; Kalmar J; Gaudino-Goering E; Shawaryn M; Moore NB; Halper J; DeLuca J
Arch Phys Med Rehabil; 2005 Dec; 86(12):2303-8. PubMed ID: 16344027
[TBL] [Abstract][Full Text] [Related]
6. Impact of an educational program on the safety of high-risk, visually impaired, older drivers.
Owsley C; McGwin G; Phillips JM; McNeal SF; Stalvey BT
Am J Prev Med; 2004 Apr; 26(3):222-9. PubMed ID: 15026102
[TBL] [Abstract][Full Text] [Related]
7. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
8. Illness and demographic correlates of chronic pain among a community-based sample of people with multiple sclerosis.
Douglas C; Wollin JA; Windsor C
Arch Phys Med Rehabil; 2008 Oct; 89(10):1923-32. PubMed ID: 18929020
[TBL] [Abstract][Full Text] [Related]
9. Randomized control trial of effects of a 10-week inspiratory muscle training program on measures of pulmonary function in persons with multiple sclerosis.
Fry DK; Pfalzer LA; Chokshi AR; Wagner MT; Jackson ES
J Neurol Phys Ther; 2007 Dec; 31(4):162-72. PubMed ID: 18172412
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of an energy conservation course for persons with multiple sclerosis.
Mathiowetz V; Matuska KM; Murphy ME
Arch Phys Med Rehabil; 2001 Apr; 82(4):449-56. PubMed ID: 11295003
[TBL] [Abstract][Full Text] [Related]
11. [Prospective assessment of the treatment of multiple sclerosis relapses with oral high-dose methylprednisolone: response and tolerability data].
Pascual AM; Boscá I; Escutia M; Bernat A; Coret F; Casanova B
Neurologia; 2008 Mar; 23(2):73-7. PubMed ID: 17641984
[TBL] [Abstract][Full Text] [Related]
12. Fitness to drive in multiple sclerosis: awareness of deficit moderates risk.
Ryan KA; Rapport LJ; Telmet Harper K; Fuerst D; Bieliauskas L; Khan O; Lisak R
J Clin Exp Neuropsychol; 2009 Jan; 31(1):126-39. PubMed ID: 18608652
[TBL] [Abstract][Full Text] [Related]
13. Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis.
Khan F; Pallant JF; Turner-Stokes L
Arch Phys Med Rehabil; 2008 Apr; 89(4):652-9. PubMed ID: 18373995
[TBL] [Abstract][Full Text] [Related]
14. [Determination of CSF guanase activity in multiple sclerosis: a comparative study on various parameters to monitor the disease activity].
Kaneshige Y; Matsumoto H; Chiba S; Hashimoto S; Noro H
Rinsho Shinkeigaku; 1989 Jul; 29(7):854-8. PubMed ID: 2805507
[TBL] [Abstract][Full Text] [Related]
15. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
[TBL] [Abstract][Full Text] [Related]
16. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.
Portaccio E; Stromillo ML; Goretti B; Zipoli V; Siracusa G; Battaglini M; Giorgio A; Bartolozzi ML; Guidi L; Sorbi S; Federico A; Amato MP; De Stefano N
Neurology; 2009 Aug; 73(7):498-503. PubMed ID: 19641173
[TBL] [Abstract][Full Text] [Related]
17. The development and validation of the impact of multiple sclerosis scale and the symptoms of multiple sclerosis scale.
McMillan L; Moore KA
Arch Phys Med Rehabil; 2006 Jun; 87(6):832-41. PubMed ID: 16731220
[TBL] [Abstract][Full Text] [Related]
18. Tried and tested: the psychometric properties of the multiple sclerosis impact scale (MSIS-29) in a population-based study.
Gray O; McDonnell G; Hawkins S
Mult Scler; 2009 Jan; 15(1):75-80. PubMed ID: 18829636
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
[TBL] [Abstract][Full Text] [Related]
20. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain.
Casado V; Romero L; Gubieras L; Alonso L; Moral E; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Arbizu T
Mult Scler; 2007 Jul; 13(6):800-4. PubMed ID: 17613609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
